JP2023548005A - 抗トランスサイレチン抗体およびその使用方法 - Google Patents

抗トランスサイレチン抗体およびその使用方法 Download PDF

Info

Publication number
JP2023548005A
JP2023548005A JP2023521103A JP2023521103A JP2023548005A JP 2023548005 A JP2023548005 A JP 2023548005A JP 2023521103 A JP2023521103 A JP 2023521103A JP 2023521103 A JP2023521103 A JP 2023521103A JP 2023548005 A JP2023548005 A JP 2023548005A
Authority
JP
Japan
Prior art keywords
seq
human subject
administering
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023548005A5 (enExample
Inventor
キニー、ジーン
ザゴ、ワグナー
トリプラネニ、ラディカ
バード、フレデリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2023548005A publication Critical patent/JP2023548005A/ja
Publication of JP2023548005A5 publication Critical patent/JP2023548005A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2023521103A 2020-10-28 2021-10-28 抗トランスサイレチン抗体およびその使用方法 Pending JP2023548005A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063106855P 2020-10-28 2020-10-28
US202063106853P 2020-10-28 2020-10-28
US63/106,855 2020-10-28
US63/106,853 2020-10-28
US202063122720P 2020-12-08 2020-12-08
US63/122,720 2020-12-08
PCT/US2021/057150 WO2022094152A1 (en) 2020-10-28 2021-10-28 Anti-transthyretin antibodies and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023548005A true JP2023548005A (ja) 2023-11-15
JP2023548005A5 JP2023548005A5 (enExample) 2024-10-31

Family

ID=81384336

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521103A Pending JP2023548005A (ja) 2020-10-28 2021-10-28 抗トランスサイレチン抗体およびその使用方法

Country Status (4)

Country Link
US (1) US20230391859A1 (enExample)
EP (1) EP4237005A4 (enExample)
JP (1) JP2023548005A (enExample)
WO (1) WO2022094152A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202434624A (zh) * 2022-11-15 2024-09-01 瑞士商紐立慕公司 治療或預防甲狀腺素運載蛋白調節之澱粉樣變性的方法
WO2024256583A1 (en) * 2023-06-14 2024-12-19 Immutrin Ltd Anti-fibril antibodies
CN122374011A (zh) 2023-12-15 2026-07-10 诺和诺德股份有限公司 稳定的液体制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532617A (ja) * 2016-07-02 2019-11-14 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10213506B2 (en) * 2014-08-26 2019-02-26 University Of Tennessee Research Foundation Targeting immunotherapy for amyloidosis
KR102410072B1 (ko) * 2014-08-29 2022-06-20 알닐람 파마슈티칼스 인코포레이티드 트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법
TWI786505B (zh) * 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
LT3329002T (lt) * 2015-07-31 2021-01-11 Alnylam Pharmaceuticals, Inc. Transtiretino (ttr) irnr kompozicijos ir jų naudojimo būdai, skirti naudoti su ttr susijusių ligų gydymui arba prevencijai
JP7017013B2 (ja) * 2016-07-02 2022-02-08 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
TWI904069B (zh) * 2017-09-29 2025-11-11 美商英特利亞醫療公司 用於ttr基因編輯及治療attr澱粉樣變性之組合物及方法
MA51223A (fr) * 2017-11-29 2020-10-07 Prothena Biosciences Ltd Formulation lyophilisée d'un anticorps monoclonal contre la transthyrétine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019532617A (ja) * 2016-07-02 2019-11-14 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AKIHIKO HOSOI ET AL.: "Novel Antibody for the Treatment of Transthyretin Amyloidosis", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 291, no. 48, JPN6025049633, 2016, pages 25096 - 25105, ISSN: 0005903019 *
EILEEN URIBE-QUEROL ET AL.: "Phagocytosis: Our Current Understanding of a Universal Biological Process", FRONTIERS IN IMMUNOLOGY, vol. Vol.11，Article number: 1066, JPN6026028222, June 2020 (2020-06-01), pages 1 - 13, ISSN: 0005903021 *
JACOB GEORGE ET AL.: "A novel monoclonal antibody targeting aggregated transthyretin facilitates its removal and functiona", EUROPEAN HEART JOURNAL, vol. 41, no. 12, JPN6025049632, 22 December 2019 (2019-12-22), pages 1260 - 1270, ISSN: 0005903020 *

Also Published As

Publication number Publication date
US20230391859A1 (en) 2023-12-07
EP4237005A1 (en) 2023-09-06
EP4237005A4 (en) 2024-10-09
WO2022094152A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
RU2518351C2 (ru) Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применения
US7785587B2 (en) Therapeutic methods for muscular or neuromuscular disorders
US20230183341A1 (en) Methods of use of anti-trem2 antibodies
US20230391859A1 (en) Anti-transthyretin antibodies and methods of use thereof
JP2021508366A (ja) 気分障害の治療及び診断のための抗−配列類似性１９を持つファミリー、メンバーａ５抗体の用途
JP2022547452A (ja) Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療
JP2025508757A (ja) 抗ｔｒｅｍ２抗体の使用方法
JP2021502955A (ja) シヌクレイン病の治療のための投与レジメン
TWI894689B (zh) 抗N3pGlu類澱粉蛋白β抗體、其劑量及其用途
US20220127346A1 (en) Methods of Safe Administration of Anti-Tau Antibody
TW202321303A (zh) 抗pla2r自體抗體媒介膜性腎病變之治療
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
KR20210041535A (ko) 항-a베타 항체 및 이의 용도
CN116507637A (zh) 抗转甲状腺素蛋白抗体及其使用方法
AU2007313170A1 (en) Methods for the treatment of muscular dystrophy associated with dysferlin-deficiency
US20260028395A1 (en) Treatment of ophthalmologic diseases
RU2844863C1 (ru) Применение молекул, связывающих семафорин-4d, для лечения синдрома ретта
HK40100364A (en) Methods of reducing tau in human subjects
Class et al. Patent application title: Methods of Reducing Tau in Human Subjects
CN116829582A (zh) 安全施用抗Tau抗体的方法
WO2026035942A1 (en) Combinatorial therapy for alzheimer's disease
EA046525B1 (ru) Система и способ контроля таблеток ядерного топлива

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230526

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241023

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260707